Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 239

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 239
---
 329,338           541,835      –             ( 541,835      –             –                           –  
  Share-based                                                                             258,645           367,983      –             883,560        –             –                   1,251,543  
  Balance,                                                                                4,265,186      24,168,256      459,341       2,523,946      ( 21,250      ( 24,022,741        3,107,552  

  (*)      On September 30, 2022 and on November 28, 2023, the Company effected 1-for-30 reverse splits of its issued and outstanding common shares, pursuant to which holders of the Company’s common share...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

(The
accompanying notes are an integral part of these consolidated financial statements)

F-6

CLEARMIND
MEDICINE INC.

Consolidated
Statements of Cash Flows

(Expressed
in United States Dollars)

                                                                                        Year                                                                                      
                                                                                        ended October 31,                                                                         
                                                                                        2024                                    2023                       2022                   
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Operating activities                                                                                                                                                            
  Net loss                                                                              $                      ( 5,254,678      $         ( 8,620,837      $         ( 6,894,868  
  Adjustments for:                                                                                                                                                                
  Amortization of intangible                                                                                        10,984                     10,954                     14,830  
  Amortization of right-of-use                                                                                      39,023                     35,381                     60,665  
  Interest on lease liability                                                                                        5,386                      2,907                     14,433  
  Exchange rate differences                                                                                          6,051                     78,171                          –  
  Issuance costs allocated                                                                                         115,046                    468,408                          –  
  Depreciation of property                                                                                           1,065                     11,175                      7,572  
  Changes in fair value of                                                                                       ( 707,802                  2,189,986                    290,569  
  Share-based compensation                                                                                         883,872                    366,405                  1,207,549